ICCM vs DBVT vs HALO vs ALKS vs ABBV

For growth investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger pick with 37. 6% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 28. 0x trailing P/E (8. 8x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Halozyme Therapeutics, Inc.

(HALO) is the cheapest at 28. 0x versus AbbVie Inc. at 94. 9x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 8x.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +127. 2%, compared to -68. 3% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: HALO returned +653. 7% versus DBVT's -89. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 17β versus IceCure Medical Ltd's 1. 85β — meaning ICCM is approximately 980% more volatile than ABBV relative to the S&P 500. On balance sheet safety, IceCure Medical Ltd (ICCM) carries a lower debt/equity ratio of 2% versus 44% for Halozyme Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Halozyme Therapeutics, Inc.

(HALO) is pulling ahead at 37. 6% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: IceCure Medical Ltd grew EPS 20. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -445. 6% for IceCure Medical Ltd — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -446. 7% for ICCM. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 8x forward P/E versus 15. 8x for AbbVie Inc. — 7. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 163. 5% to $46. 33.

In this comparison, ABBV (2.

9% yield) pays a dividend. ICCM, DBVT, HALO, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 17), 2. 9% yield, +336. 5% 10Y return). IceCure Medical Ltd (ICCM) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +336. 5%, ICCM: -52. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ICCM is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; HALO is a small-cap high-growth stock; ALKS is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock. ABBV pays a dividend while ICCM, DBVT, HALO, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.